Patents by Inventor Willard McKowan Welch

Willard McKowan Welch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
    Patent number: 6448265
    Abstract: The pyrazoles and pyrazolopyrimidines of the formula wherein R1, R2, R3, R4 and A are as defined herein, have corticotropin releasing factor (CRF) antagonist activity. As such, they are effective in the treatment of a wide range of diseases including stress-related illnesses.
    Type: Grant
    Filed: August 19, 1999
    Date of Patent: September 10, 2002
    Assignee: Pfizer, Inc.
    Inventors: William Stephen Faraci, Willard McKowan Welch, Jr.
  • Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
    Patent number: 6441018
    Abstract: The pyrazoles and pyrazolopyrimidines of the formula wherein R1, R2, R3, R4 and A are as defined herein, have corticotropin releasing factor (CRF) antagonist activity. As such, they are effective in the treatment of a wide range of diseases including stress-related illnesses.
    Type: Grant
    Filed: August 19, 1999
    Date of Patent: August 27, 2002
    Assignee: Pfizer Inc.
    Inventors: William Stephen Faraci, Willard McKowan Welch, Jr.
  • Atropisomers of 3-heteroaryl-4(3H)-quinazolinones for the treatment of neurodegenerative and CNS-trauma related conditions
    Patent number: 6380204
    Abstract: The present invention relates to novel atropisomers of 3-heteroaryl-4(3H)-quinazolinones of the formula Ia, and their pharmaceutically acceptable salts, and pharmaceutical compositions and methods of treating neurodegenerative and CNS-trauma related conditions.
    Type: Grant
    Filed: January 13, 2000
    Date of Patent: April 30, 2002
    Assignee: Pfizer INC
    Inventors: Bertrand Leo Chenard, Keith Michael Devries, Willard McKowan Welch, Jr.
  • PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONISTIC ACTIVITY
    Publication number: 20020016333
    Abstract: The pyrazoles and pyrazolopyrimidines of the formula 1
    Type: Application
    Filed: August 19, 1999
    Publication date: February 7, 2002
    Inventors: WILLIAM STEPHEN FARACI, WILLARD MCKOWAN WELCH
  • Combination of growth hormone secretagogues and antidepressants
    Publication number: 20020002137
    Abstract: This invention is directed to combinations comprising a growth hormone secretagogue, a prodrug thereof or a pharmaceutically acceptable salt of said growth hormone secretagogue or said prodrug and an antidepressant, a prodrug thereof or a pharmaceutically acceptable salt of said antidepressant or said prodrug and to pharmaceutical compositions and kits comprising such combinations. Antidepressants within the scope of this invention include norepinephrine reuptake inhibitors (e.g., secondary and tertiary amine tricyclics), selective sertraline reuptake inhibitors, agents which are combined norepinephrine/sertraline reuptake inhibitors, monoamine oxidase inhibitors and atypical antidepressants.
    Type: Application
    Filed: May 18, 2001
    Publication date: January 3, 2002
    Inventors: Frank Robert Busch, Willard McKowan Welch
  • Atropisomers of 3-aryl-4(3H)-quinazolinones and their use as AMPA-receptor antagonists
    Patent number: 6306864
    Abstract: The present invention relates to novel atropisomers of 2-(aryl or heteroaryl)-3-aryl-4(3H)-quinazolinones of the formula I, and their pharmaceutically acceptable salts, and pharmaceutical compositions and methods of treating neurodegenerative and CNS-trauma related conditions.
    Type: Grant
    Filed: January 13, 2000
    Date of Patent: October 23, 2001
    Assignee: Pfizer Inc.
    Inventors: Willard McKowan Welch, Jr., Keith Michael DeVries
  • 2-(4-hydroxypiperidino)-1-alkanol derivatives as antiischemic agents
    Patent number: 6255322
    Abstract: A series of 2-(4-hydroxypiperidino)-1-alkanol derivatives are useful as medicaments for the treatment of traumatic injuries to the brain and spinal cord and neuronal degenerative diseases including senile dementias, in mammals, especially humans.
    Type: Grant
    Filed: January 13, 1994
    Date of Patent: July 3, 2001
    Assignee: Pfizer Inc.
    Inventor: Willard McKowan Welch
  • Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
    Patent number: 6103900
    Abstract: The pyrazoles and pyzazolopyrimidines of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and A are as defined herein, have corticotropin releasing factor (CRF) antagonist activity. As such, they are effective in the treatment of a wide range of diseases including stress-related illnesses.
    Type: Grant
    Filed: October 30, 1997
    Date of Patent: August 15, 2000
    Assignee: Pfizer Inc
    Inventors: William Stephen Faraci, Willard McKowan Welch, Jr.
  • Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
    Patent number: 6005109
    Abstract: The pyrazoles and pyzazolopyrimidines of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and A are as defined herein, have corticotropin releasing factor (CRF) antagonist activity. As such, they are effective In the treatment of a wide range of diseases including stress-related illnesses.
    Type: Grant
    Filed: October 30, 1997
    Date of Patent: December 21, 1999
    Assignee: Pflizer Inc.
    Inventors: William Stephen Faraci, Willard McKowan Welch, Jr.
  • Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
    Patent number: 5712303
    Abstract: The pyrazoles and pyzazolopyrimidines of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and A are as defined herein, have corticotropin releasing factor (CRF) antagonist activity. As such, they are effective in the treatment of a wide range of diseases including stress-related illnesses.
    Type: Grant
    Filed: June 14, 1995
    Date of Patent: January 27, 1998
    Assignee: Pfizer Inc.
    Inventors: William Stephen Faraci, Willard McKowan Welch, Jr.